CASODEX (bicalutamide), antiandrogen

• CASODEX has Marketing Authorisation in the treatment of prostate cancer:

          - metastatic, in combination with medical or surgical castration, at a dosage of 50 mg/day

          - locally advanced prostate cancer, at high risk of disease progression, at a dosage of 150 mg/day, in treatment alone or as an adjuvant to radical prostatectomy or radiation therapy.

• Its therapeutic benefit remains substantial in metastatic prostate cancer, in combination with medical or surgical castration, at the dosage of 50 mg/day.
• With regard to current therapeutic methods, CASODEX has no role in the therapeutic strategy for locally advanced prostate cancer, at high risk of progression, at the dosage of 150 mg/day, either in treatment alone or as an adjuvant to radical prostatectomy or radiation therapy.